GANX
Gain Therapeutics, Inc.Healthcare·Biotechnology
$1.95
$83M market cap
Revenue
$0.0M
Free Cash Flow
$-9.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidat
2-Year Price History
$1.78-30.2%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -5.3 | -5.4 | -5.6 | -4.7 | -4.7 | -0.0 | 16.5 | 0.3 | 42.2 | <-999% | -- | -- |
| Act | 2025-Q4 | 0.0 | -4.4 | -4.5 | -4.5 | -4.6 | -4.6 | -0.0 | 20.8 | 0.7 | 33.0 | -264.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.95
Market Cap$83M
Enterprise Value$67M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-11.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-10.2M
Free Cash Flow$-9.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-769.1%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares3.4M
Days to Cover6.3
Change (vs Prior)+3.3%
Need at least 2 settlement dates for chart
Employees
Headcount23
Revenue / Employee$0
Gross Profit / Employee$0
Cash Runway
21.2months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
15.3%(+10.8% YoY)
29 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
4.2%(+2.1% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
1.7%(+1.5% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | $3.4M | $2.96 | +$209K | +$3.1M | +0.6% | $92.71B |
| Potomac Capital Management, Inc. | $2.0M | $3.22 | −$3K | +$2.0M | +0.4% | $114M |
| JONES FINANCIAL COMPANIES LLLP | $1.2M | $1.92 | −$137K | +$373K | -0.1% | $208.07B |
| Cambridge Investment Research Advisors, Inc. | $1.1M | $2.45 | +$0 | +$988K | -0.4% | $38.49B |
| DME Capital Management, LP | $1.1M | $3.77 | +$0 | +$0 | -1.5% | $3.19B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $869K | $2.68 | +$96K | +$321K | +2.3% | $1.61T |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $837K | $3.24 | −$491K | +$670K | -0.6% | $77.14B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $776K | $1.94 | +$776K | +$776K | — | $4.04T |
| GSA CAPITAL PARTNERS LLP | $606K | $1.97 | +$566K | +$606K | -5.9% | $1.61B |
| VANGUARD FIDUCIARY TRUST COPassive | $446K | $1.94 | +$446K | +$446K | — | $395.83B |
| BlackRock, Inc.Passive | $437K | $2.39 | +$30K | +$273K | -0.2% | $5.69T |
| UBS Group AG | $428K | $1.99 | +$270K | +$344K | -0.3% | $562.11B |
| JANE STREET GROUP, LLCMM | $421K | $2.84 | −$49K | +$421K | -0.1% | $92.10B |
| Cresset Asset Management, LLC | $310K | $3.22 | +$0 | +$310K | -0.0% | $23.10B |
| STATE STREET CORPPassive | $306K | $2.85 | +$0 | +$168K | -0.2% | $2.89T |
| MORGAN STANLEY | $271K | $1.98 | −$15K | +$77K | -0.3% | $1.65T |
| Stratos Wealth Partners, LTD. | $255K | $1.94 | +$255K | +$255K | -0.2% | $8.78B |
| NORTHERN TRUST CORPPassive | $221K | $2.65 | +$23K | +$27K | -0.2% | $755.34B |
| LPL Financial LLC | $202K | $3.22 | −$4K | +$202K | -0.2% | $372.65B |
| PRELUDE CAPITAL MANAGEMENT, LLC | $69K | $3.60 | +$0 | +$0 | +1.4% | $1.30B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.31%
avg per quarter
Holders (ex-self)
-0.29%
excl. this stock
Buyers (this Q)
-3.02%
10 buyers · $0.00B in
Sellers (this Q)
+0.03%
14 sellers · $0.01B out
alpha coverage: 92% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+3.5%
how holders react when this stock falls
On quiet Qs
-2.3%
−10% to +10% baseline
On rallies (+10%+)
-13.1%
how they react when this stock rises
Holders' portfolio flow this Q
+4.9%
inflows — adds are organic
Sellers' portfolio flow this Q
+8.5%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.5%
Holder mid (any stock)
-7.2%
Holder rally (any stock)
-6.1%
Biggest decreases this quarter
CITADEL ADVISORS LLC−$676Kα-0.4SUSQUEHANNA INTERNATIONAL GROUP, LLP−$491Kα-0.6Focus Partners Wealthexited−$251KHRT FINANCIAL LPexited−$179KJONES FINANCIAL COMPANIES LLLP−$137Kα-0.1OMERS ADMINISTRATION Corpexited−$120KGOLDMAN SACHS GROUP INCexited−$105KPoint72 Asset Management, L.P.exited−$105KLighthouse Investment Partners, LLCexited−$74KRENAISSANCE TECHNOLOGIES LLCexited−$56K
New buyers this quarter
Top-5 holders · 55.4%
MARSHALL WACE, LLP--
Potomac Capital Management, Inc.--
JONES FINANCIAL COMPANIES LLLP--
Cambridge Investment Research Advisors, Inc.--
DME Capital Management, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
GREENLIGHT CAPITAL INC—MARSHALL WACE, LLP1.8MPotomac Capital Management, Inc.1.0MJONES FINANCIAL COMPANIES LLLP632KDME Capital Management, LP566KCambridge Investment Research Advisors, Inc.569KGranite Point Capital Management, L.P.—RAYMOND JAMES & ASSOCIATES—Telemetry Investments, L.L.C.—ROYAL BANK OF CANADA—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (3 analysts)$8.3332720.0%
Current Price$1.95
Analyst Ratings
7
1
Buy: 7Hold: 1Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
53.7%retail-0.3pp
9.8%dark+2.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
GAIN THERAPEUTICS: A Biotech Death Spiral Fueled by Toxic Financing and Imminent Insolvency
Overall Risk
9/10
Fraud
3/10
Dilution
10/10
Insolvency
10/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
5/10
Audit Warnings
10/10
Hidden Upside
2/10
Contextually Acceptable
3/10